Texas Dermatology and Laser Specialists | San Antonio, Texas
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis.
This study will last about 68 weeks and may include up to 16 planned visits. If participating in the optional extension as well, the study will last approximately 1 additional year for a total of up to 116 weeks and may include up to 29 scheduled visits.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Note: If study KGBI is still blinded at the time of rollover to study KGBJ, conditions deemed related to the study treatment will be considered related to lebrikizumab.
Primary purpose
Allocation
Interventional model
Masking
250 participants in 2 patient groups
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal